The assessment of treatment outcomes in metastatic prostate cancer: Changing endpoints

被引：23

作者：

Dawson, NA

McLeod, DG

机构：

[1] WALTER REED ARMY MED CTR,UROL SERV,WASHINGTON,DC 20307

[2] UNIFORMED SERV UNIV HLTH SCI,BETHESDA,MD 20814

来源：

关键词：

D O I：

10.1016/S0959-8049(96)00443-1

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

[No abstract available]

引用

页码：560 / 565

页数：6

共 52 条

[1] Aaronson N K, 1988, Recent Results Cancer Res, V111, P231
[2] AHMANN FR, 1990, P AN M AM SOC CLIN, V9, P134
[3] [Anonymous], 1958, 1 10 YEARS WORLD HLT
[4] [Anonymous], P AM SOC CLIN ONCOL
[5] PROGNOSTIC-SIGNIFICANCE OF PROSTATE SPECIFIC ANTIGEN IN ENDOCRINE TREATMENT FOR PROSTATIC-CANCER
ARAI, Y
YOSHIKI, T
YOSHIDA, O
[J]. JOURNAL OF UROLOGY, 1990, 144 (06) : 1415 - 1419
[6] BLACKARD CE, 1975, CANCER CHEMOTH REP 1, V59, P225
[7] Cassileth B R, 1992, Qual Life Res, V1, P323, DOI 10.1007/BF00434946
[8] CASSILETH BR, 1991, CONTROVERSIES MANA 6
[9] THE FUNCTIONAL ASSESSMENT OF CANCER-THERAPY SCALE - DEVELOPMENT AND VALIDATION OF THE GENERAL MEASURE
CELLA, DF
TULSKY, DS
GRAY, G
SARAFIAN, B
LINN, E
BONOMI, A
SILBERMAN, M
YELLEN, SB
WINICOUR, P
BRANNON, J
ECKBERG, K
LLOYD, S
PURL, S
BLENDOWSKI, C
GOODMAN, M
BARNICLE, M
STEWART, I
MCHALE, M
BONOMI, P
KAPLAN, E
TAYLOR, S
THOMAS, CR
HARRIS, J
[J]. JOURNAL OF CLINICAL ONCOLOGY, 1993, 11 (03) : 570 - 579
[10] CITRIN DL, 1974, LANCET, V1, P1132